Cardiac Amyloidosis in HFpEF Tunisian Patients

Key facts

Sponsor

University Tunis El Manar

Principal Investigator

Lilia Zakhama, Prof

University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia

Enrollment

87 enrolled

Eligibility

60-90 years · All sexes

Timeline

2023 – 2024

Study locations (1)

• Security Hospital Forces, La Marsa, Tunis Governorate, Tunisia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07560306
  [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy
  Brigham and Women's Hospital
• RECRUITINGNCT07494656
  A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
  Pfizer
• RECRUITINGPHASE4NCT07298044
  A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
  Bayer
• RECRUITINGPHASE2NCT07285044
  The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
  Mayo Clinic
• RECRUITINGNCT07218705
  A Study Of MCG In Cardiac Amyloidosis
  Mayo Clinic
• ENROLLING BY INVITATIONPHASE2NCT06723015
  Tau PET Outcomes With Anti-amyloid Immunotherapies
  Mayo Clinic
• RECRUITINGNCT07213297
  Comprehensive Program for Hereditary Transthyretin Amyloidosis
  Hospital de Alta Complejidad en Red
• RECRUITINGPHASE1NCT06790394
  Test-retest Study With [18F]FBB in Cardiac Amyloidosis
  Life Molecular Imaging GmbH

See all trials for Amyloidosis →